Abstract：
More and more studies have revealed that P2 purinergic receptors play a key role in the progression of colorectal cancer (CRC). P2X and P2Y purinergic receptors can be used as promoters and regulators of CRC and play a dual role in the progression of CRC. CRC microenvironment is rich in ATP and its cleavage products (ADP, AMP, Ado), which act as activators of P2X and P2Y purinergic receptors. The activation of P2X and P2Y purinergic receptors regulates the progression of CRC mainly by regulating the function of immune cells and mediating different signal pathways. In this paper, we focus on the specific mechanisms and functional roles of P2X7, P2Y12, and P2Y2 receptors in the growth and progression of CRC. The antagonistic effects of these selective antagonists of P2X purinergic receptors on the growth, invasion, and metastasis of CRC were further discussed. Moreover, different studies have reported that P2X7 receptor can be used as an effective predictor of patients with CRC. All these indicate that P2 purinergic receptors are a key regulator of CRC. Therefore, antagonizing P2 purinergic receptors may be an innovative treatment for CRC.
摘要：
越来越多的研究表明,P2嘌呤能受体在结直肠癌(CRC)的发生发展中起关键作用。P2X和P2Y嘌呤能受体可用作CRC的启动子和调节因子,在CRC的进展中起着双重作用。CRC微环境中富含ATP及其裂解产物(ADP，AMP,Ado),作为P2X和P2Y嘌呤能受体的激活剂。P2X和P2Y嘌呤受体的激活主要通过调节免疫细胞的功能和介导不同的信号通路来调节CRC的进展。在本文中,我们关注P2X7,P2Y12和P2Y2受体在CRC发生发展中的具体机制和功能作用.P2X嘌呤能受体的这些选择性拮抗剂对生长的拮抗作用，入侵,进一步讨论了CRC的转移。此外，不同研究报道P2X7受体可作为CRC患者的有效预测因子。所有这些表明P2嘌呤能受体是CRC的关键调节因子。因此,拮抗P2嘌呤能受体可能是一种新的CRC治疗方法.
